PT - JOURNAL ARTICLE AU - R. Borie AU - M. Wislez AU - G. Thabut AU - M. Antoine AU - A. Rabbat AU - L-J. Couderc AU - I. Monnet AU - H. Nunes AU - F-X. Blanc AU - H. Mal AU - A. Bergeron AU - D. Dusser AU - D. Israƫl-Biet AU - B. Crestani AU - J. Cadranel TI - Clinical characteristics and prognostic factors of pulmonary MALT lymphoma AID - 10.1183/09031936.00039309 DP - 2009 Dec 01 TA - European Respiratory Journal PG - 1408--1416 VI - 34 IP - 6 4099 - http://erj.ersjournals.com/content/34/6/1408.short 4100 - http://erj.ersjournals.com/content/34/6/1408.full SO - Eur Respir J2009 Dec 01; 34 AB - Mucosa-associated lymphoid tissue-derived (MALT) lymphoma, a low grade B-cell extranodal lymphoma, is the most frequent subset of primary pulmonary lymphoma. Our objective was to evaluate the initial extent of disease and to analyse the characteristics and long-term outcome of these patients. All chest and pathological departments of teaching hospitals in Paris were contacted in order to identify patients with a histological diagnosis of primary pulmonary lymphoma of the MALT subtype. 63 cases were identified. The median age was 60 yrs. 36% of cases had no symptoms at diagnosis. 46% of patients had at least one extrapulmonary location of lymphoma. The estimated 5- and 10-yr overall survival rates were 90% and 72%, respectively. Only two of the nine observed deaths were related to lymphoma. Age and performance status were the only two adverse prognostic factors for survival. Extrapulmonary location of lymphoma was not a prognostic factor for overall survival or for progression-free survival. Treatment with cyclophosphamide or anthracyclin was associated with shorter progression-free survival, when compared with chlorambucil. The survival data confirm the indolent nature of pulmonary MALT lymphoma. Better progression-free survival was observed with chlorambucil when compared with cyclophosphamide or anthracyclin.